<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630447</url>
  </required_header>
  <id_info>
    <org_study_id>UCHC03-008CBM</org_study_id>
    <nct_id>NCT01630447</nct_id>
  </id_info>
  <brief_title>Genetic and Functional Analysis of Cherubism</brief_title>
  <acronym>CBM</acronym>
  <official_title>Identification of Mutations That Lead to Cherubism in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to identify genes and regulatory elements on chromosomes
      that cause cherubism. Together with the investigators collaborators the investigators also
      study blood samples and tissue samples from patients to learn about the processes that lead
      to this disorder. The long-term goal of researchers involved in this study is to find
      mechanisms to slow down bone resorption in cherubism patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cherubism is a very rare bone disorder where bone gets excessively resorbed only in the jaw
      bones (mandible and maxilla). The resulting cavities in bone fill up with soft fibrous
      (fibro-osseous) tissues that can expand and push the bony shells apart. Thus the
      characteristic facial appearance in patients with progressed cherubism. Bone resorption
      (cherubism lesions) in this disorder occurs always symmetrically in the mandible, the maxilla
      or in both. This distinguishes cherubism from similar disorders. As cherubism progresses, the
      lesions can invade the eye sockets (inferior and/or lateral orbital walls) and displace the
      eye balls and push down the eyelids. As a result the sclera (white of the eye) below the iris
      becomes visible and patients have an upward gazing appearance (cherubic look) which gave the
      name to this fibro-proliferative bone disorder.

      Cherubism typically appears between ages of 2-7 years. It is often diagnosed during dental
      evaluations. At early stages cherubism is accompanied by lymph node swelling. Proliferation
      of the fibro-osseous tissue typically stops after puberty and in many the soft tissue in the
      cherubic bone cavities are replaced by new bone.

      For this study we will:

        -  Send out study participation kits and consent by phone

        -  Collect a saliva sample from eligible individuals

        -  Obtain information regarding cherubism

        -  Document disorder with photos and doctor's letters

        -  If patients undergo surgery for cherubism we ask to obtain some bone tissue that would
           otherwise be discarded

        -  Isolate DNA from the saliva sample

        -  Perform genetic analyses of the DNA with the most up-to-date methods available to
           identify genetic variations

        -  Study in the laboratory why the genetic variations cause the disorder
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic elements</measure>
    <time_frame>at time of identification</time_frame>
    <description>The goal is to identify relevant genes or genetic elements that cause the disease or contribute to the disease progression and severity.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cherubism</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva, blood, bone tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with clinically diagnosed cherubism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cherubism; unaffected individuals only if part of a participating cherubism family

        Exclusion Criteria:

          -  no cherubism unaffected individuals only as part of a participating cherubism family
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst J Reichenberger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernst J Reichenberger, PhD</last_name>
    <phone>860-679-2062</phone>
    <email>reichenberger@uchc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernst J Reichenberger, PhD</last_name>
      <phone>860-679-2062</phone>
      <email>reichenberger@uchc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://health.uconn.edu/reichenberger-lab/</url>
    <description>Description of lab research and patient recruitment procedures</description>
  </link>
  <reference>
    <citation>Levaot N, Voytyuk O, Dimitriou I, Sircoulomb F, Chandrakumar A, Deckert M, Krzyzanowski PM, Scotter A, Gu S, Janmohamed S, Cong F, Simoncic PD, Ueki Y, La Rose J, Rottapel R. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell. 2011 Dec 9;147(6):1324-39. doi: 10.1016/j.cell.2011.10.045.</citation>
    <PMID>22153076</PMID>
  </reference>
  <results_reference>
    <citation>Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, Ninomiya C, doAmaral C, Peters H, Habal M, Rhee-Morris L, Doss JB, Kreiborg S, Olsen BR, Reichenberger E. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001 Jun;28(2):125-6.</citation>
    <PMID>11381256</PMID>
  </results_reference>
  <results_reference>
    <citation>Gilbert G, DÃ©fillo M, Delcan JL, David P. [Results of anastomoses in the tetralogy of Fallot]. Union Med Can. 1966 Dec;95(12):1377-84. French.</citation>
    <PMID>5996221</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, Saheki Y, Kawai T, Mukherjee PM, Reichenberger E, Olsen BR. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 &quot;cherubism&quot; mice. Cell. 2007 Jan 12;128(1):71-83.</citation>
    <PMID>17218256</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang CJ, Chen IP, Koczon-Jaremko B, Boskey AL, Ueki Y, Kuhn L, Reichenberger EJ. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties. Bone. 2010 May;46(5):1306-15. doi: 10.1016/j.bone.2010.01.380. Epub 2010 Feb 1.</citation>
    <PMID>20117257</PMID>
  </results_reference>
  <results_reference>
    <citation>Levaot N, Simoncic PD, Dimitriou ID, Scotter A, La Rose J, Ng AH, Willett TL, Wang CJ, Janmohamed S, Grynpas M, Reichenberger E, Rottapel R. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions. J Clin Invest. 2011 Aug;121(8):3244-57. doi: 10.1172/JCI45843. Epub 2011 Jul 18.</citation>
    <PMID>21765218</PMID>
  </results_reference>
  <results_reference>
    <citation>Reichenberger EJ, Levine MA, Olsen BR, Papadaki ME, Lietman SA. The role of SH3BP2 in the pathophysiology of cherubism. Orphanet J Rare Dis. 2012 May 24;7 Suppl 1:S5. doi: 10.1186/1750-1172-7-S1-S5. Epub 2012 May 24. Review.</citation>
    <PMID>22640988</PMID>
  </results_reference>
  <results_reference>
    <citation>Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: best clinical practice. Orphanet J Rare Dis. 2012 May 24;7 Suppl 1:S6. doi: 10.1186/1750-1172-7-S1-S6. Epub 2012 May 24. Review.</citation>
    <PMID>22640403</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Ernst Reichenberger</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>cherubism</keyword>
  <keyword>bone</keyword>
  <keyword>autoinflammatory disorder</keyword>
  <keyword>osteoblast</keyword>
  <keyword>osteoclast</keyword>
  <keyword>mandible</keyword>
  <keyword>maxilla</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cherubism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

